Can a weekly shot help obese teens avoid diabetes and fatty liver?
NCT ID NCT05067621
First seen Apr 30, 2026 · Last updated Jun 20, 2026 · Updated 6 times
Summary
This study tests whether semaglutide (Wegovy), a once-weekly injection, can preserve the pancreas's ability to produce insulin and reduce liver fat in 60 obese youth with prediabetes or early type 2 diabetes and fatty liver disease. Participants receive either semaglutide or a placebo for 6 months, and researchers measure changes in beta-cell function and liver fat content. The goal is to see if this drug can slow disease progression in this high-risk group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY, CHILDHOOD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pediatric Diabetes Center
New Haven, Connecticut, 06511, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Semaglutide (Wegovy), a once-weekly injection
What this could lead to
If successful, this could point toward a treatment that slows or prevents progression from prediabetes to type 2 diabetes and reduces liver fat in obese youth.
What could go wrong
This is an early phase 2 trial with only 60 participants, so results may not apply broadly. The benefits may be modest or not sustained after stopping the drug.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.